Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

3.28AUD
26 Apr 2017
Change (% chg)

$0.20 (+6.49%)
Prev Close
$3.08
Open
$3.10
Day's High
$3.29
Day's Low
$3.06
Volume
1,745,449
Avg. Vol
746,233
52-wk High
$3.29
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Mesoblast receives A$3.7m from Australian Government for research and development
Wednesday, 5 Apr 2017 07:33pm EDT 

Mesoblast Ltd :Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX.  Full Article

FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy
Monday, 3 Apr 2017 04:34pm EDT 

Mesoblast Ltd :FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease.  Full Article

IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial
Friday, 31 Mar 2017 06:00am EDT 

Mesoblast Ltd : Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial . Says interim analysis dataset has been locked and will be analyzed and reviewed by trial's independent statisticians . Mesoblast Ltd - throughout review process, co to remain blinded to individual treatment allocation as well as grouped safety and efficacy data .Mesoblast Ltd - IDMC will review and interpret results of interim analysis and provide recommendations shortly.  Full Article

Mesoblast raises US$40 million
Sunday, 26 Mar 2017 07:40pm EDT 

Mesoblast Ltd : Mesoblast raises US$40 million .Placement price of A$2.00 per share represents a 4.8 pct discount to 15 day vwap of A$2.10.  Full Article

FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease
Tuesday, 7 Mar 2017 06:00am EST 

Mesoblast Ltd : FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease .Mesoblast Ltd - Enrollment in phase 3 trial is expected to complete mid-2017 with a top-line read out in 2H CY 2017.  Full Article

Mesoblast says US FDA grants fast track designation for GVHD
Monday, 6 Mar 2017 05:54pm EST 

Mesoblast Ltd : FDA grants Mesoblast fast track designation for GVHD .FDA grants fast track designation for Mesoblast's cell therapy in children with Acute Graft Versus Host Disease.  Full Article

Mesoblast Ltd says Co and Mallinckrodt enter into agreement
Thursday, 22 Dec 2016 04:54pm EST 

Mesoblast Ltd : Asx alert-Mesoblast and Mallinckrodt enter into agreement-MSB.AX . Mallinckrodt will have exclusive period of up to 9 months to conclude commercial,development agreements for 2 product candidates in all territories outside of Japan and China .Mallinckrodt will purchase approximately 20.04 million of Mesoblast's ordinary shares at a price of A$1.4761 per share.  Full Article

Mesoblast appoints Bill Burns as vice chairman
Wednesday, 31 Aug 2016 07:49pm EDT 

Mesoblast Ltd :Mesoblast appoints Bill Burns as vice chairman Full Article

Mesoblast reports Q4 earnings per share $0.1278
Wednesday, 24 Aug 2016 06:41pm EDT 

Mesoblast Ltd : Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016 .Q4 earnings per share $0.1278.  Full Article

Mesoblast provides update on global heart failure program
Monday, 13 Jun 2016 06:55pm EDT 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

More From Around the Web

BRIEF-Mesoblast receives A$3.7m from Australian Government for research and development

* Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX Source text for Eikon: Further company coverage: